Supplemental Filings: Back To US FDA’s Conference Center, What Marks Wants In A Gene Therapy Director, And More
• By Pink Sheet Team
The FY 2023 generic drug regulatory science priorities meeting at the US FDA seemed familiar. • Source: Derrick Gingery 
